Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05894564 · ClinicalTrials.gov registry record · Phase 3
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
A Phase 3 study of COVID-19, sponsored by Susanna Naggie, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,208
- Enrollment target
- 20
- Study locations
NCT05894564: Completed Phase 3 study of COVID-19, sponsored by Susanna Naggie, MD.
NCT05894564 is a Phase 3 study of COVID-19 that has completed, run by Susanna Naggie, MD. The registered enrollment target is 1,208 participants, below the 38,461-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05894564, a Phase 3 study of COVID-19, has completed, sponsored by Susanna Naggie, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,208 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking study drug or placebo. This study is intended to be all remote with no in person visits, unless the study team feels it is in the best interest of a participant to see them in person. Prior and current drug arms are listed on clinicaltrials.gov and will be updated with the activation of any new drug arms. Each study arm will also have its own clinicaltrials.gov entry and will include "Pro00107921" in the Unique Protocol ID.
Primary Outcome
Time to sustained recovery was the number of days between receipt of study drug and the third of 3 consecutive days without symptoms. Participants who died, by definition, did not recover regardless of reported symptom freedom. The reported summary is the median survival time.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Fluvoxamine
Study Locations (20)
Florida
- Arena Medical Group - Deerfield Beach
- Lupus Foundation of Gainesville - Gainesville
- University of Florida Health - Gainesville
- L and A Morales Healthcare, Inc - Hialeah
- University of Florida-JAX-ASCENT - Jacksonville
- AMRON Vitality and Wellness Center, LLC - Jacksonville
- Sunshine Walk In Clinic - Lake Mary
- Lakeland Regional Medical Center - Lakeland
- Jackson Memorial Hospital - Miami
- University of Miami - Miami
Arizona
- Lamb Health, LLC - Gilbert
- First Care Medical Clinic - Mesa
- Trident Health Center - Peoria
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Assuta Family Medical Group APMC - North Hollywood
- Stanford - Palo Alto
Colorado
- Doctors Medical Group of Colorado Springs, P.C. - Colorado Springs
- Pine Ridge Family Medicine Inc. - Colorado Springs
Connecticut
- Tabitha B. Fortt, M.D., LLC - Stamford
District of Columbia
- George Washington University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,208 participants |
| Start Date | 2022-08-25 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 3 |
What the finished NCT05894564 record still lists
NCT05894564 is an interventional study that assigns participants to a tested intervention. Its 1,208 participants enrollment target places it among the larger protocols in the corpus, below the 38,461-participant average among 298 other COVID-19 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05894564 names 20 study sites across 6 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05894564 about?
NCT05894564 is a clinical study titled "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)". The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or med...
What is the current status of trial NCT05894564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,208 participants. The study started on 2022-08-25. Estimated completion is 2023-05-30.
What conditions does trial NCT05894564 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05894564?
The interventions under investigation include: Placebo (OTHER), Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT05894564?
This trial is sponsored by Susanna Naggie, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05894564 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05894564's enrollment target sits among peer trials
1,208 62nd of 298 higher than 237 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI